Net loss (USD)

Depreciation (USD)

Amortization of right-of-use asset (USD)

Share-based compensation expense (USD)

Change in fair value of warrant liability (USD)

PIPE warrant issuance cost (USD)

Changes in assets and liabilities: Grants receivable (Change) (USD)

Changes in assets and liabilities: Prepaid expenses and other current assets (Change) (USD)

Changes in assets and liabilities: Accounts payable and accrued expenses (Change) (USD)

Changes in assets and liabilities: Deferred grant income (Change) (USD)

Changes in assets and liabilities: Security deposit (Change) (USD)

Changes in assets and liabilities: Operating lease liability (Change) (USD)

Net cash used in operating activities (USD)

Purchase of equipment (USD)

Net cash used in investing activities (USD)

Net proceeds from issuance of common stock (USD)

Payments of deferred offering costs (USD)

Net cash provided by financing activities (USD)

Net change in cash (USD)

Supplemental disclosure of cash flow: Interest related to insurance premium payment plan (USD)

Supplemental disclosure of non-cash investing and financing activities: Exercise of Series D warrants (USD)

Supplemental disclosure of non-cash investing and financing activities: Right-of-use assets obtained in exchange for operating lease liabilities (USD)

Supplemental disclosure of non-cash investing and financing activities: Deemed dividend arising from warrant modification (USD)

Supplemental disclosure of non-cash investing and financing activities: Recognition of liability classified Series C warrants (USD)

Supplemental disclosure of non-cash investing and financing activities: Recognition of liability classified Series D warrants (USD)

Cash, beginning of period (USD)

Cash, end of period (USD)

38159f9ca1230ed6d9abd893f9437288e409091a08523ea15843ac8e8c1082da

Research and development expenses (USD)

General and administrative expenses (USD)

Total operating expenses (USD)

Operating loss (USD)

PIPE warrant Issuance Costs (USD)

Grant income (USD)

Currency exchange gain (loss) (USD)

Interest income (USD)

Interest expense (USD)

Total other income (expense) (USD)

Net loss attributable to common stockholders (USD)

Deemed dividend arising from warrant modification (USD)

Weighted-average common shares outstanding (shares)

Net loss per share (USD per share)

fcb2f5478c847a654996729edc3f797d16c2ba9e6ac8334f8c427e330990ad4b

Cash (USD)

Grant receivable (USD)

Prepaid expenses and other current assets (USD)

Total current assets (USD)

Property and equipment, net of depreciation (USD)

Right-of-use asset, net of amortization (USD)

Security deposit (USD)

Total assets (USD)

Accounts payable and accrued expenses (USD)

Deferred grant income (USD)

Short-term lease liability (USD)

Total current liabilities (USD)

Warrant Liability - Series C (USD)

Warrant Liability - Series D (USD)

Long-term lease liability (USD)

Long-term liabilities (USD)

Total liabilities (USD)

Preferred stock (USD)

Common stock (USD)

Additional paid-in capital (USD)

Accumulated deficit (USD)

Total stockholders’ equity (deficit) (USD)

Total liabilities and stockholders’ equity (deficit) (USD)

2d7ade969d94cf99970b763b128e441e02af30b2b03a1e8f55f19d71eb6912bd

- Grant Income

Total Revenue

faafb96469b53bcd6ce6d117811a7f440b051795c53a0a2c482688b4b210788a

Transcode Therapeutics Inc (RNAZ)

Financials